{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:04Z","timestamp":1787020984431,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in type 2 diabetes, yet safety data in super-elderly patients (\u2265\u200980 years) remain limited. We compared the safety of SGLT2i versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, new-user, active-comparator cohort study using the TriNetX Global Collaborative Network (176 healthcare organizations). Patients aged\u2009\u2265\u200980 years at treatment initiation with type 2 diabetes newly prescribed SGLT2i or DPP-4i were matched 1:1 using propensity scores incorporating demographics, comorbidities, frailty proxies, and concomitant medications. Primary safety outcomes included falls, hip fracture, acute kidney injury, urinary tract infection, genital candidiasis, hypoglycemia, volume depletion, hypotension, and syncope. Secondary outcomes included stroke, myocardial infarction, heart failure hospitalization, and all-cause mortality. Subgroup analyses assessed falls risk among insulin, benzodiazepine, and loop diuretic users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 65,119 patients remained in each cohort (mean age 82.2\u2009\u00b1\u20092.3 years; 48.7% female). Over a mean follow-up of 269 days, SGLT2i was associated with significantly lower risks of falls (HR 0.90; 95% CI 0.85\u20130.95), hip fracture (HR 0.78; 0.69\u20130.89), acute kidney injury (HR 0.82; 0.78\u20130.85), urinary tract infection (HR 0.79; 0.75\u20130.83), hypoglycemia (HR 0.74; 0.67\u20130.82), volume depletion (HR 0.91; 0.86\u20130.97), stroke (HR 0.88; 0.82\u20130.95), and all-cause mortality (HR 0.73; 0.70\u20130.76; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Genital candidiasis risk was higher with SGLT2i (HR 1.70; 1.50\u20131.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), as was heart failure hospitalization (HR 1.07; 1.02\u20131.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Hypotension, syncope, and myocardial infarction did not differ significantly. The falls reduction was consistent across subgroups using insulin, benzodiazepines, and loop diuretics. Sensitivity analysis with fixed 250-day follow-up confirmed all primary findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In super-elderly patients with type 2 diabetes, SGLT2i demonstrated a favorable safety profile compared to DPP-4i, with significantly lower risks of falls (10%), hip fracture (22%), acute kidney injury (18%), hypoglycemia (26%), and mortality (27%). Safety concerns included increased genital candidiasis (70%) and modestly higher heart failure hospitalization (7%). These findings support SGLT2i use in appropriately selected super-elderly patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-026-00305-4","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:02:51Z","timestamp":1782684171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of SGLT2 inhibitors versus DPP-4 inhibitors in super-elderly patients (\u2265\u200980 years) with type 2 diabetes: a propensity score-matched cohort study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2421-3953","authenticated-orcid":false,"given":"Shankar","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashasvi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Hamadttu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"305_CR1","unstructured":"Laiteerapong N, Huang ES. Diabetes in Older Adults. In: Cowie CC, Casagrande SS, Menke A, et al, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018."},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"108078","DOI":"10.1016\/j.diabres.2020.108078","volume":"162","author":"A Sinclair","year":"2020","unstructured":"Sinclair A, Saeedi P, Kaundal A, et al. Diabetes and global ageing among 65\u201399-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108078.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"305_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","volume":"12","author":"WD Strain","year":"2021","unstructured":"Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes. Diabetes Ther. 2021;12(5):1227\u201347.","journal-title":"Diabetes Ther"},{"issue":"6","key":"305_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","volume":"48","author":"P Monteiro","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial. Age Ageing. 2019;48(6):859\u201366.","journal-title":"Age Ageing"},{"issue":"2","key":"305_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020;43(2):468\u201375.","journal-title":"Diabetes Care"},{"issue":"7","key":"305_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"305_CR7","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/bcp.14539","volume":"86","author":"RJ van Marum","year":"2020","unstructured":"van Marum RJ. Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol. 2020;86(10):2014\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"305_CR8","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S244-S257.","DOI":"10.2337\/dc24-S013"},{"issue":"39","key":"305_CR9","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"10","key":"305_CR10","doi-asserted-by":"publisher","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","volume":"4","author":"M Zhuo","year":"2021","unstructured":"Zhuo M, Hawley CE, Paik JM, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"305_CR11","doi-asserted-by":"publisher","first-page":"afac201","DOI":"10.1093\/ageing\/afac201","volume":"51","author":"M Evans","year":"2022","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51(10):afac201.","journal-title":"Age Ageing"},{"key":"305_CR12","doi-asserted-by":"publisher","first-page":"204209862110723","DOI":"10.1177\/20420986211072383","volume":"13","author":"K Doni","year":"2022","unstructured":"Doni K, B\u00fchn S, Weise A, et al. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Drug Saf. 2022;13:20420986211072383.","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"305_CR13","doi-asserted-by":"publisher","first-page":"101275","DOI":"10.1016\/j.diabet.2021.101275","volume":"47","author":"AJ Scheen","year":"2021","unstructured":"Scheen AJ. Efficacy\/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes Metab. 2021;47(6):101275.","journal-title":"Diabetes Metab"},{"issue":"2","key":"305_CR14","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035.","journal-title":"JAMIA Open"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, et al. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol Biol Sci Med Sci. 2018;73:980\u20137.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","volume":"55","author":"JB Segal","year":"2017","unstructured":"Segal JB, et al. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care. 2017;55:716\u201322.","journal-title":"Med Care"},{"issue":"3","key":"305_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jama.2009.2024","volume":"303","author":"ME Tinetti","year":"2010","unstructured":"Tinetti ME, Kumar C. The patient who falls: It\u2019s always a trade-off. JAMA. 2010;303:258\u201366.","journal-title":"JAMA"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.7326\/M21-0893","volume":"175","author":"E Patorno","year":"2021","unstructured":"Patorno E, et al. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;175:1528\u201341.","journal-title":"Ann Intern Med"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"12","key":"305_CR21","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00198-023-06908-2","volume":"34","author":"W Wang","year":"2023","unstructured":"Wang W, Li Y, Liu Y, et al. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int. 2023;34(12):2055\u201365.","journal-title":"Osteoporos Int"},{"issue":"4","key":"305_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.hfc.2022.03.008","volume":"18","author":"C Arnott","year":"2022","unstructured":"Arnott C, Fletcher RA, Neal B. Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. Heart Fail Clin. 2022;18(4):645\u201354.","journal-title":"Heart Fail Clin"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2337\/dc07-1152","volume":"31","author":"AV Schwartz","year":"2008","unstructured":"Schwartz AV, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391\u20136.","journal-title":"Diabetes Care"},{"key":"305_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"305_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"305_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"305_CR27","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor meta-analysis cardio-renal trialists\u2019 consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials."},{"key":"305_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215\u201325.","journal-title":"Diabetologia"},{"key":"305_CR29","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee; 13. Older Adults: Standards of Care in Diabetes\u20142025. Diabetes Care 1. January 2025; 48 (Supplement_1): S266\u2013S282. https:\/\/doi.org\/10.2337\/dc25-S013.","DOI":"10.2337\/dc25-S013"},{"key":"305_CR30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"305_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"305_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","volume":"30","author":"P Nyirjesy","year":"2014","unstructured":"Nyirjesy P, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109\u201319.","journal-title":"Curr Med Res Opin"},{"key":"305_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21:434\u20138. https:\/\/doi.org\/10.1111\/dom.13531.","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00305-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:02:55Z","timestamp":1782684175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00305-4","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used the TriNetX Global Collaborative Network, which provides access to de-identified, aggregated real-world electronic health record data. Analyses were conducted on de-identified data within the TriNetX platform; therefore, the study was considered exempt from institutional review board approval in accordance with applicable regulations. Consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}